Data shown is for informational purposes only and does not constitute investment advice. TopFund is not SEBI-registered. Consult a SEBI-registered advisor before investing.
Senores Pharmaceuticals IPO
Price Band
₹372.0–391.0
Issue Size
₹582.11 Cr
Lot Size
38 shares
Min Investment
₹14,858
GMP
+₹284.0 (72.63%)
Issue Price
₹391.0
Subject to Sauda
₹8200
Paid only if allotted
Senores Pharmaceuticals IPO AI Summary
- Senores Pharmaceuticals IPO is listed on BSE, NSE in the Pharmaceuticals sector.
- Price band: ₹372.0–₹391.0 per share, lot size 38 shares (min. investment ₹14,858).
- Subscription window: 20 Dec–24 Dec 2024, listing on 30 Dec 2024.
- Current GMP is +₹284.0 (72.63%), an estimated listing price of ₹675 — unofficial and can change daily.
Senores Pharmaceuticals Limited is set to enter the market with an IPO priced at ₹391 per share, aiming to raise ₹582.11 Cr. The company has shown significant growth in revenue and profit over recent periods, although the latest figures are for a 9-month period, which may not be directly comparable to full-year results.
TopFund is not SEBI-registered — this is educational analysis, not personalized investment advice.
Senores Pharmaceuticals IPO — Third-Party Research Views
Reviews below reflect analyst calls made before this IPO closed on 24 Dec 2024 — not a current signal.
9 of 10 reviewers say Positive
Recommendations are sourced from third-party research firms and are not TopFund's own investment advice.
Important Dates
Subscription Status
Subscription data unavailable
Senores Pharmaceuticals IPO Grey Market Premium (GMP) Today
GMP
+₹284.0
GMP %
+72.63%
Est. Listing
₹675.0
Updated: 25 Jul 2026 14:02
About the Company
Incorporated in December 2017, Senores Pharmaceuticals Limited develops and manufactures a range of pharmaceutical products primarily for the regulated markets of the US, Canada, and the UK, while also serving emerging markets. The company's product portfolio consists of Amphetamine Sulfate Tablets, Hydroxychloroquine Sulfate Tablets, Ketoconazole Tablets, Butalbital, Acetaminophen and Caffeine Capsules, Mexiletine Hydrochloride Capsules, Ketorolac Tromethamine Tablets, Diclofenac Potassium Tablets, Diclofenac Potassium Tablets, Nicardipine Hydrochloride Capsules, Escitalopram Tablets, Prochlorperazine Maleate Tablets USP, Terazosin Capsules USP, Morphine Sulfate Tablets, Methadone Hydrochloride Tablets, Cyclobenzaprine Hydrochloride Tablets, Irbesartan Tablets, Risperidone Tablets Topiramate Capsules, and Ivermectin Tablets for regulated markets. As of September 30, 2024, the company has launched 55 products in key therapeutic areas, including antibiotics and anti-fungal treatments. They have established partnerships with distributors and hospitals across several states in India. As of September 30, 2024, the company operates three dedicated R&D facilities in India and the US. The company operates in Emerging Markets across 43 countries and manufactures critical care injectables and APIs. The company's manufacturing unit is situated in Ahmedabad, Gujrat. Competitive Strength The company serves the US, Canada, and the UK regulated markets with its US FDA-approved manufacturing facility. A unique product portfolio tailored for regulated markets developed in a brief period. Long-term marketing agreements with pharmaceutical companies in the US, Canada, and the United Kingdom regulated markets. Presence in the Emerging Markets with a product portfolio, including speciality or complex products. Robust R&D capabilities driving our differentiated portfolio of products. Experieced Management Team
Company Financials (₹ Cr)
As of 2024-09-30
| Period Ended | 30 Sep 2024 | 31 Mar 2024 | 31 Mar 2023 | 31 Mar 2022 |
|---|---|---|---|---|
| Assets | 678.08 | 621.88 | 131.05 | 59.15 |
| Total Income | 183.35 | 217.34 | 39.02 | 14.63 |
| Profit After Tax | 23.94 | 32.71 | 8.43 | 0.99 |
| NET Worth | 319.06 | 231.71 | 45.50 | 36.59 |
| Reserves and Surplus | 263.36 | 175.94 | 35.25 | 25.37 |
| Total Borrowing | 242.03 | 248.38 | 60.76 | 14.21 |
Key Ratios
EPS
₹9.83
NAV
₹66.96
ROE
23.60%
ROCE
11.73%
RoNW
23.60%
P/B Value
5.84
P/E Ratio
39.77
Market Cap
₹1350.70 Cr
PAT Margin
15.25%
Debt/Equity
1.07
Peer Comparison
| Company | NAV | RoNW | EPS Basic | EPS Diluted | P/E (x) |
|---|---|---|---|---|---|
| Strides Pharma Science Ltd | 225.43 | -4.44% | -7.76 | -7.76 | — |
| Gland Pharma Limited | 529.65 | 9.26% | 46.9 | 46.9 | 37.27 |
| Caplin Point Laboratories Ltd. | 309.03 | 21.69% | 60.79 | 59.9 | 40.84 |
| Alembic Ltd. | 245.12 | 13.4% | 31.33 | 31.33 | 33.9 |
| Ajanta Pharma Ltd. | 281.6 | 23.47% | 64.82 | 64.77 | 43.34 |
| Senores Pharmaceuticals Limited This IPO | 66.96 | 23.6% | 13.67 | 13.67 | — |
Promoters
Swapnil Jatinbhai Shah and Ashokkumar Vijaysinh Barot
Objects of the Issue
The Company proposes to utilise the Net Proceeds from the Issue towards the following objects: # Issue Objects Est Amt (₹ Cr.) 1 Investment in one of the Subsidiaries, Havix, to fund capital expenditure requirements for setting up a manufacturing facility for the production of sterile injections in our Atlanta Facility 107.00 2 Re-payment/pre-payment, in full or in part, of certain borrowings availed by the Company 73.48 3 Investment in our Subsidiary, namely, Havix, for re- payment/pre-payment in full or in part, of certain borrowings availed by such Subsidiaries 20.22 4 Funding the working capital requirements of the Company 43.26 5 Investment in the Subsidiaries, namely, SPI and Ratnatris to fund their working capital requirements 59.48 6 Funding inorganic growth through acquisition and other strategic initiatives and general corporate purposes 154.37
IPO Evaluation
Generated 23 Sep 2026Revenue Trend
Total income was ₹39.02 Cr in the year ending 31 Mar 2023, rising to ₹217.34 Cr by 31 Mar 2024. However, for the period ending 30 Sep 2024, total income decreased to ₹183.35 Cr, though this is a 9-month figure, not a full year, so isn't directly comparable.
Profit Trend
Profit after tax was ₹8.43 Cr in the year ending 31 Mar 2023, increasing to ₹32.71 Cr by 31 Mar 2024. For the period ending 30 Sep 2024, profit after tax was ₹23.94 Cr, though this is a 9-month figure, not a full year, so isn't directly comparable.
Valuation
Senores Pharmaceuticals Limited has an implied P/E ratio of 39.77 at the issue price, compared to peers trading at P/E ratios ranging from 33.9 to 43.34.
Grey Market Premium, Explained
The Grey Market Premium (GMP) indicates the expected listing price of an IPO based on unofficial trading before the stock is listed on the stock exchange. A positive GMP suggests that the stock is anticipated to list at a higher price than the issue price.
Who This IPO Suits
Investors comfortable with short-term volatility and a long-term horizon typically weigh IPOs like this against their investment goals and risk tolerance. It is essential to consider the company's growth potential and market position.
Who May Want to Wait
Investors who prefer stable, established companies with a consistent track record may want to avoid this IPO, as it operates in a competitive and potentially volatile sector.
IPO Timeline, Explained
The IPO opens for subscription from December 20, 2024, to December 24, 2024. Allotment of shares will be done on December 26, 2024, and the stock is expected to be listed on December 30, 2024.
Listing Gains — The Risk
While many investors hope for listing gains, the stock's performance on the listing day can be unpredictable. Factors such as market sentiment, demand for the stock, and overall market conditions can influence the listing price.
This evaluation is generated from Senores Pharmaceuticals's own public IPO filing data for educational purposes and is not investment advice or a recommendation to apply, subscribe to, or avoid this issue — see Broker Recommendations below for named third-party research views (clearly attributed, not TopFund's own). TopFund is not a SEBI-registered investment adviser — see our Disclaimer.
Frequently Asked Questions
What is Senores Pharmaceuticals IPO GMP today?
Senores Pharmaceuticals IPO GMP today is +₹284.0 (72.63%), indicating an estimated listing price of ₹675. GMP is an unofficial grey-market indicator and can change daily.
What is the price band of Senores Pharmaceuticals IPO?
The price band of Senores Pharmaceuticals IPO is ₹372.0–₹391.0 per share.
When does Senores Pharmaceuticals IPO open and close?
Senores Pharmaceuticals IPO opens on 20 December 2024 and closes on 24 December 2024.
When does Senores Pharmaceuticals IPO list on the stock exchange?
Senores Pharmaceuticals IPO listed on 30 December 2024 at ₹675.0.
What is the lot size for Senores Pharmaceuticals IPO?
The lot size for Senores Pharmaceuticals IPO is 38 shares, requiring a minimum investment of ₹14,858.
What is the lot size for the IPO?
The lot size for Senores Pharmaceuticals' IPO is 38 shares.
What is the minimum investment required?
The minimum investment required is ₹14,858.
What is the price band for the IPO?
The price band for the IPO is ₹372 to ₹391.
When does the IPO open and close?
The IPO opens on December 20, 2024, and closes on December 24, 2024.
What does GMP mean?
GMP stands for Grey Market Premium, which indicates the expected listing price of the IPO based on unofficial trading.
Issue Details
Investor Allocation
Registrar
Lead Managers / Book Running
IPO Timeline
Open
20 Dec 2024
Close
24 Dec 2024
Allotment
26 Dec 2024
Listing
30 Dec 2024
Similar IPOs in Pharmaceuticals
Plan Your IPO Investment
Related Articles
Community Sentiment
What are other investors planning for Senores Pharmaceuticals?
No votes yet — be the first to share your view.
Sign in to voteDiscussion
User-generated content — not investment advice, and not verified or endorsed by TopFund.
No comments yet — start the discussion.